SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02956993
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
The research study is designed to assess the technical feasibility and safety of a
perivascular injection of vonapanitase delivered via micro-infusion catheter to the distal
popliteal, tibial or peroneal arteries immediately following successful angioplasty.
Name: vonapanitase
Type: Drug
Vonapanitase
Name: Placebo
Type: Drug
Placebo
Primary Outcomes
Description: Safety assessments include physical exams and routine serum chemistry and hematology tests
Measure: Incidence of adverse events
Time: Up to 6 months following study drug administration
Description: Technical success of study drug administration will be assessed by the extent of circumferential and longitudinal coverage of the artery using a protocol-defined assessment scale
Measure: Technical success of perivascular injection
Time: Intraprocedural
Other Outcomes
Measure: Minimum lumen diameter [MLD]
Time: Intraprocedural and 6 months following study drug administration
Measure: Minimum lumen area [MLA]
Time: Intraprocedural and 6 months following study drug administration
Measure: Incidence of arterial occlusion
Time: 14 days and 6 months following study drug administration
Measure: Rutherford category
Time: 14 and 28 days, and 6 months following study drug administration
Measure: Ankle-brachial index [ABI]
Time: 14 days and 6 months following study drug administration
Measure: Vascular Quality of Life Questionnaire-6 [VascuQol-6
Time: 14 days and 6 months following study drug administration
Purpose: Treatment
Allocation: Randomized
Parallel Assignment
There is one SNP
SNPs
1 G20210A
6. Known hypercoagulable state (e.g., protein C deficiency, factor V Leiden, prothrombin
G20210A mutation). --- G20210A ---
HPO Nodes
HPO:Peripheral arterial stenosis
Genes 31
AGXT MPL LDLRAP1 LDLR FBN1 APOE THPO APOB MAT2A ABCG8 MYH11 TGFB2 LMNA ELN FOXE3 ABCC6 SMAD4 JAK2 TGFBR2 MFAP5 ELN SMAD3 MYH11 LOX PCSK9 ACTA2 TGFB3 PRKG1 TGFBR1 MYLK ABCG5 hr>